The French pharmaceutical group Sanofi will invest more than 600 million euros (approximately 888 million Canadian dollars) in a new plant near the Canadian city of Toronto, in particular to manufacture a vaccine against the flu, he announced. Wednesday.
“This installation is expected to be operational in 2026,” the group said in a statement to AFP.
The project, which represents “an investment of more than 600 million euros”, aims in particular to manufacture a vaccine developed by the group against influenza to increase its availability in Canada, Europe and the United States.
Marketed under the name Efluelda, it is a so-called “quadrivalent” vaccine, that is to say which protects against four strains of the influenza virus, for a wider protection. It is approved in most European countries.
“This investment is part of Sanofi’s overall growth strategy, in which vaccines are an essential growth lever,” said the group.
The announcement comes as the group has been overtaken by several competitors, such as Pfizer and AstraZeneca, in the race for COVID vaccines. He has two projects underway, which will not lead to a launch until the end of the year at the earliest.
Sanofi is also the subject of criticism from its unions for initiating cutbacks in research, but the group has regularly stressed that they do not concern vaccines.
He also announced last year an investment of 500 million euros to create a new factory in France as well as a research center, both dedicated to vaccines.
Get the latest news delivered to your inbox
Follow us on social media networks